GondolaBio›GondolaBio› offers Hereditary Pancreatitis Program

Hereditary pancreatitis programs compete on mechanism breadth and timing: GondolaBio's lead-optimization candidate sits inside a portfolio approach in which affiliate companies and shared discovery infrastructure let the company advance multiple genetic drivers in parallel.

The company's spinout backing—BridgeBio-originated assets plus a $300 million financing commitment—provides longer runway at this stage than standalone preclinical competitors in the indication.

GondolaBio's hereditary pancreatitis program was first listed by the company in a BridgeBio investor presentation filed with the SEC in January 2025, appearing at lead-optimization stage roughly five months after the August 2024 spinout that transferred the initial protoporphyria, alpha-1 antitrypsin deficiency, and tuberous sclerosis programs.

The program has not been publicly named or assigned a candidate code, and its mechanism has not been disclosed; independent pancreatitis advocacy pipeline trackers catalogue it as a preclinical, undisclosed-target effort in the same patient population as trypsin-directed approaches.

Hereditary pancreatitis affects tens of thousands of patients worldwide, with pain and recurrent inflammation as the dominant clinical burden and no approved disease-modifying treatment.

Development in the space spans trypsin-directed antibodies, gene therapy, and small molecules at preclinical or IND-enabling stage, so first-to-clinic proof of mechanism will define the treatment market for the next decade.

GondolaBio's hereditary pancreatitis program targets the roughly 30,000 patients in the United States and European Union affected by hereditary pancreatitis, a genetic disease with no approved targeted therapy.

The candidate is listed at lead optimization and remains undisclosed in both target and modality, sitting inside GondolaBio's broader genetic-disease pipeline that spans small molecules, biologics, and antisense approaches.